388 related articles for article (PubMed ID: 34217426)
1. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
[TBL] [Abstract][Full Text] [Related]
2. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
[TBL] [Abstract][Full Text] [Related]
3. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
[TBL] [Abstract][Full Text] [Related]
4. Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus-Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities-New South Wales Prospective Implementation Study.
Amin J; Vaccher S; Templeton DJ; Bavinton B; Jin F; Zablotska I; Matthews G; Ogilvie E; Yeung B; Ooi C; Dharan N; Baker DA; Read P; Guy R; Grulich AE
Clin Infect Dis; 2022 Oct; 75(9):1497-1502. PubMed ID: 35352102
[TBL] [Abstract][Full Text] [Related]
5. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection.
Traeger MW; Cornelisse VJ; Asselin J; Price B; Roth NJ; Willcox J; Tee BK; Fairley CK; Chang CC; Armishaw J; Vujovic O; Penn M; Cundill P; Forgan-Smith G; Gall J; Pickett C; Lal L; Mak A; Spelman TD; Nguyen L; Murphy DA; Ryan KE; El-Hayek C; West M; Ruth S; Batrouney C; Lockwood JT; Hoy JF; Hellard ME; Stoové MA; Wright EJ;
JAMA; 2019 Apr; 321(14):1380-1390. PubMed ID: 30964528
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
[TBL] [Abstract][Full Text] [Related]
7. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
8. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
9. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
[TBL] [Abstract][Full Text] [Related]
10. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
Traeger MW; Guy R; Asselin J; Patel P; Carter A; Wright EJ; Grulich A; McManus H; Fairley CK; Chow EPF; McNulty A; Finlayson R; Bell C; Owen L; Marshall L; Russell D; O'Donnell D; Donovan B; Hellard ME; Stoové MA;
Lancet Infect Dis; 2022 Aug; 22(8):1231-1241. PubMed ID: 35643090
[TBL] [Abstract][Full Text] [Related]
11. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
[TBL] [Abstract][Full Text] [Related]
12. Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia.
Jin F; Amin J; Guy R; Vaccher S; Selvey C; Zablotska I; Holden J; Price K; Yeung B; Ogilvie E; Quichua GC; Clackett S; McNulty A; Smith D; Templeton DJ; Bavinton B; Grulich AE;
AIDS; 2021 Oct; 35(12):1987-1996. PubMed ID: 34101630
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
[TBL] [Abstract][Full Text] [Related]
14. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
Veloso VG; Cáceres CF; Hoagland B; Moreira RI; Vega-Ramírez H; Konda KA; Leite IC; Bautista-Arredondo S; Vinícius de Lacerda M; Valdez Madruga J; Farias A; Lima JN; Zonta R; Lauria L; Tamayo CVO; Flores HJS; Santa Cruz YMC; Aguayo RMM; Cunha M; Moreira J; Makkeda AR; Díaz S; Guanira JV; Vermandere H; Benedetti M; Ingold HL; Pimenta MC; Torres TS; Grinsztejn B;
Lancet HIV; 2023 Feb; 10(2):e84-e96. PubMed ID: 36565708
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Human Immunodeficiency Virus (HIV) Seroconversions in a Large Prospective Implementation Cohort Study of Oral HIV Preexposure Prophylaxis in Men Who Have Sex with Men (EPIC-NSW).
Dharan NJ; Jin F; Vaccher S; Bavinton B; Yeung B; Guy R; Carr A; Zablotska I; Amin J; Read P; Templeton DJ; Ooi C; Martin SJ; Ryder N; Smith DE; McNulty A; Brown K; Price K; Holden J; Grulich AE;
Clin Infect Dis; 2023 Feb; 76(3):e622-e628. PubMed ID: 35982613
[TBL] [Abstract][Full Text] [Related]
16. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack S; Dunn DT; Desai M; Dolling DI; Gafos M; Gilson R; Sullivan AK; Clarke A; Reeves I; Schembri G; Mackie N; Bowman C; Lacey CJ; Apea V; Brady M; Fox J; Taylor S; Antonucci S; Khoo SH; Rooney J; Nardone A; Fisher M; McOwan A; Phillips AN; Johnson AM; Gazzard B; Gill ON
Lancet; 2016 Jan; 387(10013):53-60. PubMed ID: 26364263
[TBL] [Abstract][Full Text] [Related]
17. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
19. Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial.
Chan C; Fraser D; Vaccher S; Yeung B; Jin F; Amin J; Dharan NJ; Carr A; Ooi C; Vaughan M; Holden J; Power C; Grulich AE; Bavinton BR;
Sex Health; 2022 Jan; 18(6):453-459. PubMed ID: 34895427
[TBL] [Abstract][Full Text] [Related]
20. HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study.
Laurent C; Dembélé Keita B; Yaya I; Le Guicher G; Sagaon-Teyssier L; Agboyibor MK; Coulibaly A; Traoré I; Malan JB; De Baetselier I; Eubanks A; Riegel L; Rojas Castro D; Fayé-Ketté H; Koné A; Diandé S; Dagnra CA; Serrano L; Diallo F; Mensah E; Dah TTE; Anoma C; Vuylsteke B; Spire B;
Lancet HIV; 2021 Jul; 8(7):e420-e428. PubMed ID: 34048794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
